22289933-9224-46e9-a9c4-f0b6f1947490
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.400
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- PANCREAS_BETA_CELLS+0.300
- PROTEIN_SECRETION+0.300
- DNA_REPAIR+0.200
- NOTCH_SIGNALING+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- ADIPOGENESIS+0.100
- CHOLESTEROL_HOMEOSTASIS+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- ANGIOGENESIS-0.400
- INFLAMMATORY_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- APICAL_SURFACE-0.300
- COMPLEMENT-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclc2008_S40.txt | — | cohortSC | 0.867 |
| 2 | ERR2598229 | fetal | fetal | 0.828 |
| 3 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.825 |
| 4 | ERR2598102 | fetal | fetal | 0.823 |
| 5 | MDT-AP-0540 | Med | Medulloblastoma | 0.820 |
| 6 | MDT-AP-3307 | Med | Medulloblastoma | 0.820 |
| 7 | MDT-AP-0155 | Med | Medulloblastoma | 0.820 |
| 8 | fd3ce752-3456-4aaf-bede-9cf5f0771b9d | — | — | 0.817 |
| 9 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.817 |
| 10 | ERR2598198 | fetal | fetal | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |